Stockscreener 앱 받기
1.32
2.94%
-0.04
시간 외 거래:
1.31
-0.01
-0.76%
전일 마감가:
$1.36
열려 있는:
$1.35
하루 거래량:
357.53K
Relative Volume:
0.46
시가총액:
$80.26M
수익:
-
순이익/손실:
$-24.25M
주가수익비율:
-1.9423
EPS:
-0.6796
순현금흐름:
$-19.95M
1주 성능:
+1.54%
1개월 성능:
+4.76%
6개월 성능:
+7.32%
1년 성능:
-23.26%
1일 변동 폭
$1.29
$1.355
1주일 범위
$1.25
$1.43
52주 변동 폭
$0.87
$3.19
MAIA Biotechnology Inc Stock (MAIA) Company Profile
명칭
MAIA Biotechnology Inc
전화
312 416 8592
주소
444 West Lake Street, Suite 1700, Chicago
Compare MAIA vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MAIA
MAIA Biotechnology Inc
|
1.32 | 82.69M | 0 | -24.25M | -19.95M | -0.6796 |
VRTX
Vertex Pharmaceuticals Inc
|
453.17 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.73 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
878.49 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
281.90 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
156.58 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
MAIA Biotechnology Inc 주식(MAIA)의 최신 뉴스
MAIA Biotechnology Holds Steady at $1.30, Consolidating Between Support and ResistanceETF Creation Redemption - newsline.com
MAIA Biotechnology (MAIA) Holds Steady at $1.30 as Consolidation Phase EmergesStock News - newsline.com
MAIA Biotechnology Activates and Opens Enrollment at Second U.S. Clinical Site for International Phase 2 THIO-101 Expansion Trial - Yahoo Finance
MAIA Q1 2026 Earnings: EPS Beat on Lower Net Loss, Focus on Clinical PipelineConsensus Beat Rate - newsline.com
MAIA Biotechnology Q1 2026 Earnings: Narrower-than-Expected Loss Amid Clinical ProgressEPS Consistency Score - newsline.com
MAIA Biotechnology Inc. (MAIA) announced that its pivotal Phase III clinical trial for non-small cell lung cancer is showing strong momentum in patient enrollment and dosing. - Bitget
MAIA Biotechnology Reports Strong Enrollment and Dosing Momentum in Pivotal Phase 3 Non-Small Cell Lung Cancer Trial - The Manila Times
MAIA Biotechnology Reports Patient Enrollment Progress in Phase 3 Trial of Telomere-Targeting Therapy for Advanced Non-Small Cell Lung Cancer - Quiver Quantitative
Lung cancer trial drug saw 17.8-month survival vs 5.8 on chemo in MAIA study - Stock Titan
MAIA Biotechnology Receives FDA Clearance to Open U.S. Enrollment in Ongoing Phase 2 THIO-101 Trial Expansion - The Manila Times
FDA clears U.S. trial of MAIA lung cancer drug for third-line patients - Stock Titan
Top MAIA Biotechnology Insiders Make Bold Moves With Fresh Stock Purchases - TipRanks
Maia Biotechnology CSO Sergei Gryaznov buys $2,690 in common stock By Investing.com - Investing.com Canada
MAIA Biotechnology Announces Open Market Purchases by CEO and Director - The Manila Times
MAIA Biotechnology Executives Increase Stock Holdings, Express Confidence in Cancer Immunotherapy Development - Quiver Quantitative
Maia Biotechnology director Stan Smith buys $100,200 in company stock By Investing.com - Investing.com Australia
Maia Biotechnology CEO Vlad Vitoc buys $100,885 in company stock - Investing.com UK
Maia Biotechnology CSO Sergei Gryaznov buys $2,690 in common stock - Investing.com
Maia Biotechnology director Stan Smith buys $100,200 in company stock - Investing.com
Maia Biotechnology CEO Vlad Vitoc buys $100,885 in company stock By Investing.com - Investing.com India
MAIA Biotechnology (MAIA) CEO Vitoc Vlad adds 72,700 shares in open-market buy - Stock Titan
Director Stan Smith adds 75,000 MAIA (NASDAQ: MAIA) shares via trust purchase - Stock Titan
MAIA (MAIA) Chief Scientific Officer purchases 2,000 company shares in market trade - Stock Titan
MAIA (MAIA) CEO awarded 800,000 stock options at $1.39 exercise price - Stock Titan
MAIA Biotechnology (MAIA) grants CSO 400,000 stock options at $1.39 - Stock Titan
MAIA Biotechnology (MAIA) grants 60,000 stock options to head of finance - Stock Titan
MAIA Biotechnology Presents Trial in Progress Poster for Pivotal Phase 3 Clinical Trial of Novel Telomere Targeting Agent at 2026 Annual Meeting of American Society of Clinical Oncology - The Manila Times
MAIA Biotechnology presents Phase 3 trial design for novel lung cancer drug at ASCO 2026 - Pluang
MAIA Biotechnology Inc. (MAIA) Surges 7.75%: Potential Breakout Above Key Resistance?Institutional Buy Signals - The Legal Advocate
MAIA Biotechnology Inc. (MAIA) Gains 3.91% as Biotech Momentum Lifts Shares from Support LevelsBreakaway Gap - thelegaladvocate.com
MAIA Biotechnology Q1 2026 Earnings: Narrower-Than-Expected Loss Highlights Continued Pipeline ProgressProfit Guidance Range - The Legal Advocate
MAIA Biotechnology, Inc. 8-K Filing: Annual Meeting Results, Company Details, and NYSE American Listing - Minichart
Maia Biotechnology shareholders re-elect directors and ratify auditor at annual meeting By Investing.com - Investing.com South Africa
Maia Biotechnology shareholders re-elect directors and ratify auditor at annual meeting - Investing.com Australia
MAIA Biotechnology Shareholders Back Board and Auditor Appointments - TipRanks
MAIA Biotechnology (MAIA) investors back 2026 directors and auditor at meeting - Stock Titan
MAIA Biotechnology (MAIA) Q1 2026 Earnings Surprise: EPS $-0.14, Up SignificantEarnings Expansion Phase - newsline.com
Diamond Equity Research Releases Update Note on MAIA Biotechnology, Inc. (NYSE: MAIA) - Yahoo Finance
MAIA Biotechnology (MAIA) Flat at $1.26 — Consolidation Continues 2026-05-18Beta Signals - newser.com
MAIA (NASDAQ: MAIA) Solas Capital and F. T. Golden report 7.1% ownership - Stock Titan
MAIA Biotechnology Ends ATM Stock Offering Agreement - TipRanks
Maia BiotechnologyTo Terminate At The Market Offering Agreement Effective May 23, 2026SEC Filing - TradingView
MAIA Biotechnology (MAIA) halts ATM share sales and terminates program - Stock Titan
MAIA (NYSE American) terminates ATM with H.C. Wainwright after $5.68M raised - Stock Titan
TradingKey - TradingKey
MAIA Biotechnology (NYSEAMERICAN:MAIA) Posts Earnings Results, Beats Estimates By $0.04 EPS - MarketBeat
MAIA Biotechnology (MAIA) delivers Q4 earnings beat, cutting losses by 32% as clinical pipeline advances.Market Expert Watchlist - Newser
MAIA Biotechnology, Inc. 1Q 2026: Net income $(6.37M), EPS $(0.14) — 10-Q Summary - TradingView
MAIA Biotechnology (MAIA) boosts cash with $33M raise as NSCLC trials advance - Stock Titan
MAIA Biotechnology | 424B5: Prospectus - Moomoo
Short Interest in MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) Rises By 23.0% - MarketBeat
MAIA Biotechnology Inc (MAIA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.27%
1.43%
자본화:
|
볼륨(24시간):